AbbVie (NYSE: ABBV) reported updated results from its Phase 2 EPCORE NHL-6 trial evaluating outpatient administration of epcoritamab for patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE